How safe is the food we eat? How safe and effective are the drugs we take and the medical devices we use? What about the cars we drive and the consumer products we buy? These are questions one might expect various agencies of the federal government -- the U.S. Department of Agriculture, the Food & Drug Administration, the National Highway Traffic Safety Administration, and the Consumer Product Safety Commission -- to answer with quick and reassuring replies. Unfortunately, examples of unsafe products in recent years have been far too common, and in some cases, all too deadly.
The endocrine disruptor BPA can be found in baby bottles, water bottles, and in the resin lining of food and beverage cans. Federal action to protect Americans from its potential harm has been achingly slow. CPR Member Scholars propose solutions in the form of a federal action plan.
In the last two years of his Administration, President Obama faces a Congress united by party and fundamentally at odds with the agenda he intends to pursue. CPR's Issue Alert offers a path to genuine accomplishment for the President: 13 Essential Regulatory Actions.
In the view of CPR's Thomas McGarity, the Bush Administration's 2003 response to the outbreak of Mad Cow Disease in the United States laid bare the problems with an enforcement agency that is first and foremost a cheerleader for agri-business.
In early 2010, auto manufacturer Toyota was forced to recall millions of vehicles because of life-threatening safety problems -- some of the cars accelerated out of control, other cars refused to respond promptly to braking. The problems had begun to emerge years earlier and had been reported to the National Highway Traffic Safety Administration. But the agency failed to act in a meaningful way, exposing drivers to years of unnecessary risk.
Similar problems have plagued the Food and Drug Administration (FDA). In late 2004, pharmaceutical manufacturer Merck & Co. Inc. announced that it was voluntarily withdrawing its blockbuster pain medication, Vioxx. The company revealed that a clinical trial had demonstrated that long-term use of the pain-relief product resulted in a nearly doubled risk of heart attack or stroke. Some 20 million people had taken drug by then. Should the Food & Drug Administration have known earlier? Should it have recognized the risks, and denied approval to the product, or at the very least insisted on more research to rule out the possibility? According to The Hidden Lesson of the Vioxx Fiasco: Reviving a Hollow FDA, a 2005 report from CPR’s Rena Steinzor and Margaret Clune Giblin, FDA failed to protect the public in the Vioxx case because it had become an example of a “hollow government” agency – lacking the resources to do its job adequately, and missing the political will to fight for those resources and to reign in companies eager to take excessive risks.
The hollow FDA has proven equally unable to ensure that the foods we eat are safe from contamination. The CDC estimates that each year 48 million Americans (one in six) suffer from foodborne illness, resulting in 128,000 hospitalizations and more than 3,000 deaths. A substantial portion of these illnesses are caused by produce, processed foods, and seafood under the FDA’s jurisdiction, much of it imported from developing countries with ineffective regulatory systems. And yet in 2011, the FDA was able to inspect only 0.4 percent of foreign food facilities and check just 2 percent of food imports at the border. In the final days of 2010, Congress passed the Food Safety Modernization Act (FSMA) in an effort to overhaul the nation’s food safety system and shift the FDA’s focus from reaction to prevention. But the FDA’s attempts to implement the law were soon met with long delays at the White House, vigorous opposition from sectors of the food industry, and resistance from House Republicans. CPR is monitoring the law’s implementation to ensure the resulting rules provide the maximum benefits to public health and safety.
Food Safety Modernization Regs
In 2012, the FDA sent to the White House Office of Information and Regulatory Affairs (OIRA) two rules to implement parts of the Food Safety Modernization Act. OIRA is required to limit its reviews to no more than 120 days, but these rules sat with OIRA for 13 months, a not uncommon scenario. When OIRA finally returned the rules to FDA, they were, in the words of CPR's Thomas McGarity and Policy Analyst Michael Patoka, "gutted." In November 2013, McGarity and Patoka joined CPR Member Scholars Lisa Heinzerling, Sidney Shapiro and Rena Steinzor, in filing comments on the proposed rules, one on raw produce, and the other on preventive controls for human food production.
The proposed produce rule addresses some of the most likely sources of contamination on farms, including tools and equipment, water used in agricultural activities, and worker health and hygiene. But according to a careful analysis by CPR, contained in the scholars' comments, the cost-benefit analysis conducted for the rule badly exaggerates the costs to industry of complying. As an example, the comments note that the post-OIRA version of the rule calculates the cost of workers washing their hands before handling food, at the beginning of the day, after touching a farm animal, or after going to the bathroom. The calculated cost: $113.5 million. As Lisa Heinzerling writes, "the FDA effectively reverses this common-sense presumption [that people should wash their hands after visiting the bathroom] by treating hand washing as a departure from the existing norm and, as such, an imposition of costs on the farm worker’s employer. Reversing the presumption in favor of hand washing makes even less sense when one recalls that most farms are alreadyrequired to allow their workers 'reasonable use' of hand-washing facilities."
Other examples abound. Tainted peanut butter, toxic drywall, lead-laden imported toys, and more. Such instances of unsafe food, drugs, automobiles and products are all too dangerous evidence of a failed system of regulation and enforcement. Often the failure is the result of neglect – a lack of political will to spend the money required to conduct meaningful research and enforcement. Sometimes the cause is ideological: a conviction that government should “get off industry’s back,” because such regulation is unnecessary, that the “rare” instances of unsafe products are self-correcting for the manufacturer, because they would suffer economic consequences. That argument likely holds little appeal to the families of the estimated 88,000 or more Americans who suffered heart attacks because they took Vioxx, or whose loved ones were harmed or killed by unsafe food, cars or consumer products.
Learn about CPR Member Scholars’ work to ensure the safety and efficacy of the nation’s drugs and medical devices, and the safety of the nation’s food supply:
Compounding Pharmacies. Read Rena Steinzor's February 28, 2015 op-ed in USA Today on the real-world impact of 2013 legislation passed in the wake of a meningitis outbreak caused by contaminated medicine from the New England Compounding Center.
Poultry Processing. On April 9, 2013, CPR Member Scholar Rena Steinzor and CPR Policy Analyst Michael Patoka sent a letter to the Acting Head of the Office of Information and Regulatory Affairs about the unexamined environmental implications of a USDA proposal to replace government inspectors on poultry processing lines with company employees, while speeding up the processing line to 175 birds per minute.
BPA. Read about CPR Member Scholars work on bisphenol A, the dangerous substance found in baby bottles, food cans, and more.
Toyota Recalls. On February 9, 2010, CPR Member Scholars Rena Steinzor and Sidney Shapiro sent a letter to the House Oversight and Government Reform Committee outlining important questions it should put to the National Highway Traffic Safety Administration, in the wake of its failure to force speedy action on safety problems with several Toyota models. Read the letter. Or read Steinzor and Shapiro's February 22, 2010 editorial memo on the same subject.
Senate Testimony: Medical Devices. CPR's Thomas McGarity testified before the Senate HELP Committee on August 4, 2009, declaring that current FDA regulation of medical devices was inadequate in the absence of a the right to sue for damages in state civil courts. Read the news release. Read the testimony.